This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
European Society for Medical Oncology (ESMO) Congress 2024 was held in Barcelona, Spain, bringing together the global oncology community to share the latest...
The Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program (MDPNP) directs the Secretary of Health and Human Services (HHS) to set a maximum...
CRA is a proud sponsor of the event honoring Pulitzer prize-winning journalist, Andrea Elliott, author of Invisible Child: Poverty, Survival, and Hope in an...
CRA is a proud sponsor of the event supporting the not-for-profit public interest foundation whose mission is promoting public discourse on the proper role of...
